Trinity Biotech (TRIB) announced that its Premier Hb9210 HbA1c Analyser with its recently launched next-generation Buffer A Plus column system has achieved the prestigious Gold Classification from the International Federation of Clinical Chemistry and Laboratory Medicine for 2026. This marks a historic milestone as the Premier Hb9210 HbA1c Analyser is the only HbA1c system worldwide to earn this highest level of HbA1c manufacturer’s certification for 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech files to sell 55.89M American depositary shares
- Trinity Biotech Restructures Perceptive Debt With New $5 Million Term Loan and Expanded ADS Conversion Rights
- Trinity Biotech enters series of agreements with Perceptive Advisors funds
- Trinity Biotech Files Mid‑2025 Unaudited Interim Results with U.S. Regulators
- Trinity Biotech Wins 9 Million-Test HIV Order and Returns to Profitability in Q3 2025